Aviv Ladanie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7684008/publications.pdf

Version: 2024-02-01

1163117 1474206 10 223 8 9 citations h-index g-index papers 10 10 10 309 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study. Journal of Clinical Epidemiology, 2020, 118, 29-41.	5.0	13
2	Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Network Open, 2020, 3, e2024406.	5.9	53
3	Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. Journal of Clinical Epidemiology, 2019, 114, 49-59.	5.0	20
4	Current use and costs of electronic health records for clinical trial research: a descriptive study. CMAJ Open, 2019, 7, E23-E32.	2.4	44
5	Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis. Journal of Clinical Epidemiology, 2019, 107, 12-26.	5.0	8
6	Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. Journal of Clinical Epidemiology, 2018, 94, 35-45.	5.0	11
7	Interpretation of epidemiologic studies very often lacked adequate consideration of confounding. Journal of Clinical Epidemiology, 2018, 93, 94-102.	5.0	40
8	The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. Trials, 2018, 19, 505.	1.6	17
9	How to use FDA drug approval documents for evidence syntheses. BMJ: British Medical Journal, 2018, 362, k2815.	2.3	17
10	Off-label prescription: experience is a gloomy lantern that does not even illuminate its bearer. Author response. Journal of Clinical Epidemiology, 2018, 101, 127-128.	5.0	0